CLEC9A and cancer: Notably, the DNGR-1 receptor (also called CLEC9A orCD370) was recently found to bind F-actin–myosin and confercross-presentation of phagocytosed antigens on MHC-I to direct CD8+ T cell responses.224 Given thepolymeric fiber-like structure of F-actin–myosin and desirabilityof CD8+ T cell-directed responses in cancer immunotherapy,synthetic DNGR-1 agonists are an attractive area for future study.Developing strategies to synthesize polymeric agonists of these receptorsand target appropriate cell subsets with specificity will result innovel applications of biomaterials.